Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers ADCs have become mainstream therapies ...

Discover the latest targeted therapies and clinical trials for FR-alpha–positive ovarian cancer, including antibody-drug ...

This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.

Human DLBCL, ALCL and multiple myeloma (MM) cell lines were cultured as previously described in RPMI (Life Technologies, Carlsbad, CA, USA) with 10% fetal calf serum (Sigma-Aldrich, St Louis, MO, USA) ...